Supercharged immune cells take on Hard-to-Treat head and neck cancer

This trial tested a new treatment for people with Epstein-Barr virus (EBV)-positive head and neck cancer that has spread or come back. The treatment uses specially engineered immune cells (TCR-T cells) that recognize EBV on cancer cells and also release a PD1 blocker to help them work better in the tumor environment. Ten participants received different doses to find the safest and most effective dose. The goal was to see if these cells could control the cancer, but ongoing management is still needed.